| Mr Robert M Gladstone, RPH | |
|
150 Park St, Lawrence, MA 01841-2517 | |
| (978) 686-4453 | |
| Not Available |
| Full Name | Mr Robert M Gladstone |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 150 Park St, Lawrence, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093923898 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 16258 (Massachusetts) | Primary |
| 183500000X | Pharmacist | R1023 (New Hampshire) | Secondary |
| 183500000X | Pharmacist | 6043 (Connecticut) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Robert M Gladstone, RPH 150 Park St, Lawrence, MA 01841-2517 Ph: (978) 686-4453 | Mr Robert M Gladstone, RPH 150 Park St, Lawrence, MA 01841-2517 Ph: (978) 686-4453 |
News Archive
Ten months into the COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it is unclear how people with hypertension are coping, given their increased risk. A retrospective case-control study compared people with hypertension to matched healthy controls during COVID-19 lockdown to determine whether they have higher risk perceptions, anxiety, and prevention intentions. The study is published on the preprint server medRxiv* in October 2020.
West Australian researchers from Edith Cowan University have managed to develop a blood test that is capable of diagnosing melanomas before they can spread to other parts of the body. The study titled, "A diagnostic autoantibody signature for primary cutaneous melanoma," was published in the latest issue of the journal Oncotarget.
U.S. families provide nearly $36 billion annually in uncompensated medical care at home to children who have special health care needs, such as muscular dystrophy and cystic fibrosis, according to a large national study.
Reviva Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the discovery and development of new, safer and highly effective therapies for chronic indications, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration for its lead, new investigational antipsychotic drug, RP5063.
› Verified 4 days ago
Rithy Meas, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 135 Broadway, Lawrence, MA 01840 Phone: 978-725-3221 | |
Dr. Houry Daghlian, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 73 Winthrop Ave, Lawrence, MA 01843 Phone: 978-687-0445 | |
Dr. Alicia Mam Dacunha, PHARMD, AE-C, BCACP Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 73d Winthrop Ave, Lawrence, MA 01843 Phone: 978-689-6790 | |
Dr. Olga Cristina Tejada, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 73d Winthrop Ave, Pharmacy, Lawrence, MA 01843 Phone: 978-689-6790 | |
Mrs. Rosaly V Ulrich, PHARM.D-RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 34 Haverhill St, Lawrence, MA 01841 Phone: 978-857-3858 | |
Dr. Shardul S Patel, PHARM.D., R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 34 Haverhill St, Lawrence, MA 01841 Phone: 978-806-0024 Fax: 978-494-4141 |